This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Health Management Associates Inc. (HMA): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Health Management Associates ( HMA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.4%. By the end of trading, Health Management Associates fell $0.20 (-1.6%) to $12.58 on light volume. Throughout the day, 4,571,821 shares of Health Management Associates exchanged hands as compared to its average daily volume of 6,752,100 shares. The stock ranged in price between $12.46-$12.73 after having opened the day at $12.70 as compared to the previous trading day's close of $12.78. Other companies within the Health Care sector that declined today were: Biodel ( BIOD), down 29.8%, Nymox Pharmaceutical Corporation ( NYMX), down 9.3%, Inovio Pharmaceuticals ( INO), down 8.6% and Allied Healthcare Products ( AHPI), down 8.4%.

Health Management Associates, Inc. provides general acute care health services in non-urban communities. The Company operates 32 general acute care hospitals with a total of 4,379 licensed beds, and four psychiatric hospitals with a total of 286 licensed beds. Health Management Associates has a market cap of $3.3 billion and is part of the health services industry. Shares are up 37.1% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Health Management Associates a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Health Management Associates as a hold. Among the primary strengths of the company is its solid stock price performance. At the same time, however, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 53.7%, Neuralstem ( CUR), up 18.4%, Chimerix ( CMRX), up 16.7% and Receptos ( RCPT), up 14.4% , were all gainers within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs